ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Baloxavir marboxil-related information on Douyin and Xiaohongshu: a cross-sectional analysis of content, misinformation, and user engagement.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baloxavir marboxil is a novel antiviral agent; however, the accuracy of medication-related information available on social media remains uncertain. This study aimed to systematically evaluate the content coverage, quality, and reliability of short videos related to baloxavir marboxil on Douyin and Xiaohongshu. The top 100 baloxavir marboxil-related videos were collected from both Douyin and Xiaohongshu. Quality and reliability were assessed using the JAMA criteria, modified DISCERN (mDISCERN), Global Quality Score (GQS), and the medication information items (MII) checklist. Correlations between video quality and user engagement metrics were also analyzed. A total of 176 eligible videos were included. While videos on Xiaohongshu demonstrated higher quality and reliability than those on Douyin, Douyin videos showed greater engagement. Median JAMA scores were 2.00 (Xiaohongshu) and 1.00 (Douyin); mDISCERN scores were 2.00 on both; GQS scores were 3.00 on both; and MII values were 3.00 and 2.00, respectively. A substantial proportion of videos scored poorly on JAMA-2, JAMA-4, mDISCERN-2, and mDISCERN-4. Physicians and individual users were the main uploaders. Most videos employed a monologue format and focused on indications. Videos uploaded by pharmacists had higher quality and greater medication information coverage, and were the most engaging. Although video quality was not correlated with popularity, MII was a significant predictor of high-quality videos. Misinformation mainly involved exaggerated efficacy, pharmacological misunderstandings, inappropriate self-medication, incorrect indications, misleading safety claims, and commercial exaggeration. The quality and reliability of baloxavir marboxil-related videos on Douyin and Xiaohongshu remain suboptimal, with notable deficiencies in source referencing. Significant differences in video quality exist between platforms, highlighting the need for users to exercise discernment when accessing related content. This study underscores potential disparities in access to high-quality health information across user groups on short video platforms, as well as the associated health equity issues. Future efforts should focus on characterizing misinformation related to baloxavir marboxil on short video platforms. Additionally, social media platforms should establish policies to review and monitor health education content to ensure the public receives accurate and trustworthy health information.
Indexed as
Identifiers
42696143What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.